Fecal transplants in spondyloarthritis and uveitis

Ready for a clinical trial?

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Purpose of review The intestinal microbiome is thought to play a role in the pathogenesis of inflammatory bowel disease (IBD). There are many shared clinical manifestations between IBD and spondyloarthritis (SpA), of which the most common are peripheral arthritis and uveitis. Clinical overlap along with similar genetics between these diseases suggests a possible shared pathogenetic mechanism, which might center on the intestinal microbiota. In this review, we discuss the available evidence that SpA is a microbiome-driven disease and indicate how SpA-associated uveitis could be tied to gut dysbiosis. We conclude by discussing different treatment paradigms targeting the intestinal microbiome for SpA. Recent findings Recent studies support the growing evidence of the intestinal microbiome as a crucial player in SpA disease pathogenesis. There is emerging evidence that the gut microbiome may play a causative role in uveitis. Summary The field is beginning to discover a new level of understanding how the intestinal microbiome is involved in SpA. Treatment methods to alter intestinal microbiota to treat SpA-related diseases are still in its infancy.

Original languageEnglish (US)
Pages (from-to)303-309
Number of pages7
JournalCurrent Opinion in Rheumatology
Volume30
Issue number4
DOIs
StatePublished - Jul 1 2018

Fingerprint

Uveitis
Clinical Trials
Inflammatory Bowel Diseases
Dysbiosis
Inborn Genetic Diseases
Microbiota
Gastrointestinal Microbiome
Fecal Microbiota Transplantation
Arthritis
Therapeutics

Keywords

  • ankylosing spondylitis
  • HLA-B27
  • Microbiome
  • spondyloarthritis
  • Uveitis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Fecal transplants in spondyloarthritis and uveitis : Ready for a clinical trial? / Choi, Rene Y.; Asquith, Mark; Rosenbaum, James (Jim).

In: Current Opinion in Rheumatology, Vol. 30, No. 4, 01.07.2018, p. 303-309.

Research output: Contribution to journalReview article

@article{311f59e1fbf44bec81f9a298c7496e44,
title = "Fecal transplants in spondyloarthritis and uveitis: Ready for a clinical trial?",
abstract = "Purpose of review The intestinal microbiome is thought to play a role in the pathogenesis of inflammatory bowel disease (IBD). There are many shared clinical manifestations between IBD and spondyloarthritis (SpA), of which the most common are peripheral arthritis and uveitis. Clinical overlap along with similar genetics between these diseases suggests a possible shared pathogenetic mechanism, which might center on the intestinal microbiota. In this review, we discuss the available evidence that SpA is a microbiome-driven disease and indicate how SpA-associated uveitis could be tied to gut dysbiosis. We conclude by discussing different treatment paradigms targeting the intestinal microbiome for SpA. Recent findings Recent studies support the growing evidence of the intestinal microbiome as a crucial player in SpA disease pathogenesis. There is emerging evidence that the gut microbiome may play a causative role in uveitis. Summary The field is beginning to discover a new level of understanding how the intestinal microbiome is involved in SpA. Treatment methods to alter intestinal microbiota to treat SpA-related diseases are still in its infancy.",
keywords = "ankylosing spondylitis, HLA-B27, Microbiome, spondyloarthritis, Uveitis",
author = "Choi, {Rene Y.} and Mark Asquith and Rosenbaum, {James (Jim)}",
year = "2018",
month = "7",
day = "1",
doi = "10.1097/BOR.0000000000000506",
language = "English (US)",
volume = "30",
pages = "303--309",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Fecal transplants in spondyloarthritis and uveitis

T2 - Ready for a clinical trial?

AU - Choi, Rene Y.

AU - Asquith, Mark

AU - Rosenbaum, James (Jim)

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Purpose of review The intestinal microbiome is thought to play a role in the pathogenesis of inflammatory bowel disease (IBD). There are many shared clinical manifestations between IBD and spondyloarthritis (SpA), of which the most common are peripheral arthritis and uveitis. Clinical overlap along with similar genetics between these diseases suggests a possible shared pathogenetic mechanism, which might center on the intestinal microbiota. In this review, we discuss the available evidence that SpA is a microbiome-driven disease and indicate how SpA-associated uveitis could be tied to gut dysbiosis. We conclude by discussing different treatment paradigms targeting the intestinal microbiome for SpA. Recent findings Recent studies support the growing evidence of the intestinal microbiome as a crucial player in SpA disease pathogenesis. There is emerging evidence that the gut microbiome may play a causative role in uveitis. Summary The field is beginning to discover a new level of understanding how the intestinal microbiome is involved in SpA. Treatment methods to alter intestinal microbiota to treat SpA-related diseases are still in its infancy.

AB - Purpose of review The intestinal microbiome is thought to play a role in the pathogenesis of inflammatory bowel disease (IBD). There are many shared clinical manifestations between IBD and spondyloarthritis (SpA), of which the most common are peripheral arthritis and uveitis. Clinical overlap along with similar genetics between these diseases suggests a possible shared pathogenetic mechanism, which might center on the intestinal microbiota. In this review, we discuss the available evidence that SpA is a microbiome-driven disease and indicate how SpA-associated uveitis could be tied to gut dysbiosis. We conclude by discussing different treatment paradigms targeting the intestinal microbiome for SpA. Recent findings Recent studies support the growing evidence of the intestinal microbiome as a crucial player in SpA disease pathogenesis. There is emerging evidence that the gut microbiome may play a causative role in uveitis. Summary The field is beginning to discover a new level of understanding how the intestinal microbiome is involved in SpA. Treatment methods to alter intestinal microbiota to treat SpA-related diseases are still in its infancy.

KW - ankylosing spondylitis

KW - HLA-B27

KW - Microbiome

KW - spondyloarthritis

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=85048283841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048283841&partnerID=8YFLogxK

U2 - 10.1097/BOR.0000000000000506

DO - 10.1097/BOR.0000000000000506

M3 - Review article

VL - 30

SP - 303

EP - 309

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 4

ER -